We are live on ! Find out more
ACIU icon

AC Immune

37 hedge funds and large institutions have $30.1M invested in AC Immune in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

9% more funds holding

Funds holding: 3437 (+3)

0.89% more ownership

Funds ownership: 16.78%17.67% (+0.89%)

11% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 9

32% less capital invested

Capital invested by funds: $44.3M → $30.1M (-$14.2M)

66% less call options, than puts

Call options by funds: $12K | Put options by funds: $35K

Holders
37
Holders Change
+3
Holders Change %
+8.82%
% of All Funds
0.59%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
8
Reduced
9
Closed
5
Calls
$12K
Puts
$35K
Net Calls
-$23K
Net Calls Change
-$48K

ACIU Hedge Fund Activity: Q4 2022 in Review

37 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q4 2022, worth a combined $30.1M — down 32% from $44.3M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new ACIU positions and 5 closed out — a net gain of 4 holders — while 8 added to existing stakes and 9 trimmed.

The largest buyer was Assenagon Asset Management, opening a new position worth an estimated $1.53M. The largest seller was BlackRock, cutting an estimated $938K.

  • 37 institutional investors held AC Immune (ACIU) as of Q4 2022, up from 34 in Q3 2022.
  • Funds reported $30.1M of AC Immune stock for Q4 2022, down 32% quarter-over-quarter.
  • 9 funds opened new AC Immune positions in Q4 2022 and 5 closed out, a net change of +4 holders.
  • The largest AC Immune buyer in Q4 2022 was Assenagon Asset Management, an estimated $1.53M added.
  • The largest AC Immune seller in Q4 2022 was BlackRock, an estimated $938K sold.

Based on aggregated 13F filings for Q4 2022.